211 related articles for article (PubMed ID: 22801851)
41. Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings.
Lepore D; Quinn GE; Molle F; Baldascino A; Orazi L; Sammartino M; Purcaro V; Giannantonio C; Papacci P; Romagnoli C
Ophthalmology; 2014 Nov; 121(11):2212-9. PubMed ID: 25001158
[TBL] [Abstract][Full Text] [Related]
42. [VEGF antibodies as therapy for retinopathy of prematurity].
Oberacher-Velten IM; Helbig H
Klin Monbl Augenheilkd; 2010 Sep; 227(9):694-700. PubMed ID: 20845249
[TBL] [Abstract][Full Text] [Related]
43. Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity.
Travassos A; Teixeira S; Ferreira P; Regadas I; Travassos AS; Esperancinha FE; Prieto I; Pires G; van Velze R; Valido A; Machado Mdo C
Ophthalmic Surg Lasers Imaging; 2007; 38(3):233-7. PubMed ID: 17552391
[TBL] [Abstract][Full Text] [Related]
44. Structural consequences after intravitreal bevacizumab injection without increasing apoptotic cell death in a retinopathy of prematurity mouse model.
Akkoyun I; Karabay G; Haberal N; Dagdeviren A; Yilmaz G; Oto S; Erkanli L; Akova YA
Acta Ophthalmol; 2012 Sep; 90(6):564-70. PubMed ID: 20698831
[TBL] [Abstract][Full Text] [Related]
45. Long-term effect of antiangiogenic therapy for retinopathy of prematurity up to 5 years of follow-up.
Martínez-Castellanos MA; Schwartz S; Hernández-Rojas ML; Kon-Jara VA; García-Aguirre G; Guerrero-Naranjo JL; Chan RV; Quiroz-Mercado H
Retina; 2013 Feb; 33(2):329-38. PubMed ID: 23099498
[TBL] [Abstract][Full Text] [Related]
46. Late recurrence of retinopathy of prematurity after treatment with both intravitreal bevacizumab and laser.
Chen W; Binenbaum G; Karp K; Baumritter A; Pearson DJ; Maguire AM; Quinn GE
J AAPOS; 2014 Aug; 18(4):402-4. PubMed ID: 25087645
[TBL] [Abstract][Full Text] [Related]
47. An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in taiwan.
Wu WC; Kuo HK; Yeh PT; Yang CM; Lai CC; Chen SN
Am J Ophthalmol; 2013 Jan; 155(1):150-158.e1. PubMed ID: 22967867
[TBL] [Abstract][Full Text] [Related]
48. [Retinopathy of prematurity - therapy. Part 2].
Prepiaková Z; Tomčíková D; Kostolná B; Gerinec A
Cesk Slov Oftalmol; 2014 Apr; 70(2):50-4. PubMed ID: 25030312
[TBL] [Abstract][Full Text] [Related]
49. Outcomes after Intravitreal Bevacizumab versus Laser Photocoagulation for Retinopathy of Prematurity: A 5-Year Retrospective Analysis.
Hwang CK; Hubbard GB; Hutchinson AK; Lambert SR
Ophthalmology; 2015 May; 122(5):1008-15. PubMed ID: 25687024
[TBL] [Abstract][Full Text] [Related]
50. A Surgical Technique for the Management of Tractional Retinal Detachment in Aggressive Posterior Retinopathy of Prematurity Treated With Intravitreal Bevacizumab.
De la Huerta I; Yonekawa Y; Thomas BJ; Capone A
Retina; 2019 Oct; 39 Suppl 1():S156-S159. PubMed ID: 30198966
[No Abstract] [Full Text] [Related]
51. PROGRESSIVE RETINAL DETACHMENT IN INFANTS WITH RETINOPATHY OF PREMATURITY TREATED WITH INTRAVITREAL BEVACIZUMAB OR RANIBIZUMAB.
Yonekawa Y; Wu WC; Nitulescu CE; Chan RVP; Thanos A; Thomas BJ; Todorich B; Drenser KA; Trese MT; Capone A
Retina; 2018 Jun; 38(6):1079-1083. PubMed ID: 28471890
[TBL] [Abstract][Full Text] [Related]
52. Role of VEGF Inhibition in the Treatment of Retinopathy of Prematurity.
Eldweik L; Mantagos IS
Semin Ophthalmol; 2016; 31(1-2):163-8. PubMed ID: 26959143
[TBL] [Abstract][Full Text] [Related]
53. Fellow Eye Anti-VEGF 'Crunch' Effect in Retinopathy of Prematurity.
Wood EH; Rao P; Moysidis SN; Dedania VS; Elman MJ; Drenser KA; Capone A; Trese MT
Ophthalmic Surg Lasers Imaging Retina; 2018 Sep; 49(9):e102-e104. PubMed ID: 30222828
[TBL] [Abstract][Full Text] [Related]
54. Bevacizumab versus diode laser in stage 3 posterior retinopathy of prematurity.
Moran S; O'Keefe M; Hartnett C; Lanigan B; Murphy J; Donoghue V
Acta Ophthalmol; 2014 Sep; 92(6):e496-7. PubMed ID: 24428792
[No Abstract] [Full Text] [Related]
55. Retinal fluorescein angiographic changes following intravitreal anti-VEGF therapy.
Henaine-Berra A; Garcia-Aguirre G; Quiroz-Mercado H; Martinez-Castellanos MA
J AAPOS; 2014 Apr; 18(2):120-3. PubMed ID: 24698606
[TBL] [Abstract][Full Text] [Related]
56. Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in taiwan.
Wu WC; Yeh PT; Chen SN; Yang CM; Lai CC; Kuo HK
Ophthalmology; 2011 Jan; 118(1):176-83. PubMed ID: 20673589
[TBL] [Abstract][Full Text] [Related]
57. Early vitreoretinal surgery on vascularly active stage 4 retinopathy of prematurity through the preoperative intravitreal bevacizumab injection.
Xu Y; Zhang Q; Kang X; Zhu Y; Li J; Chen Y; Zhao P
Acta Ophthalmol; 2013 Jun; 91(4):e304-10. PubMed ID: 23647944
[TBL] [Abstract][Full Text] [Related]
58. Globe size and bevacizumab treatment in retinopathy of prematurity: should we adjust the dose?
Connor AJ; Shafiq A
Eye (Lond); 2016 Nov; 30(11):1401-1403. PubMed ID: 27472209
[No Abstract] [Full Text] [Related]
59. REPORT OF SAFETY OF THE USE OF A SHORT 32G NEEDLE FOR INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS FOR RETINOPATHY OF PREMATURITY: A Multicenter Study.
Cernichiaro-Espinosa LA; Harper CA; Read SP; Wright LM; Scribbick FW; Young R; Negron CI; Rodríguez A; Berrocal AM
Retina; 2018 Jun; 38(6):1251-1255. PubMed ID: 29689029
[No Abstract] [Full Text] [Related]
60. Concentration of vascular endothelial growth factor in aqueous humor of eyes with advanced retinopathy of prematurity before and after intravitreal injection of bevacizumab.
Nonobe NI; Kachi S; Kondo M; Takai Y; Takemoto K; Nakayama A; Hayakawa M; Terasaki H
Retina; 2009 May; 29(5):579-85. PubMed ID: 19430279
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]